Mawdsleys

Mawdsleys is the largest independent pharmaceutical wholesalers in the UK with a fast-growing international network supplying medicines to meet patient needs and providing a route to market for manufacturers.

With a history tracing back to 1825, Mawdsleys has the pedigree and resources to be the reliable and experienced supplier of choice to hospitals and pharmacies around the world.

Company Type
Twitter Account
@MawdsleysUK
News Page URL
Click here

Medherant

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.  

The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.

As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.

Company Type
Twitter Account
@medherant
News Page URL
Click here

MediWales

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Company Type
Twitter Account
@mediwales
News Page URL
Click here

MGB Biopharma

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.

Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections. MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Company Type
Twitter Account
@MGB_Biopharma
News Page URL
Click here

Mironid

Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins. 

Company Type
Twitter Account
@mironidltd
News Page URL
Click here

Moxie Works

If your business needs a creative marketing and media team, choose one that understands how to communicate your field of expertise with an inside view.

MoxieWorks is a creative marketing and media agency that sees things from your side. We were the in–house media and marketing team for a group of inter–related businesses in London and this has given us a unique insight into which marketing strategies are appropriate for the most effective outcome.

Our team is fluent in the language of science and business and we use this skill to help life science companies boost brand awareness. Through concise marketing and media strategies, we can help you drive demand with measurable outcomes.

We work closely with our clients to distil their specialist knowledge into integrated marketing campaigns that leverage our key services:  marketing strategy, planning, website, photography/videography and content creation. 

Company Type
Twitter Account
n/a
News Page URL
Click here

OBN (UK) Ltd

OBN is the not-for-profit Membership organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Our 400-plus Member companies are located across the Golden Triangle and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland, benefiting from our networking, partnering, purchasing, training, advising and advocacy activities.

Company Type
Twitter Account
‎@OBN_UK
News Page URL
Click here

OFX

OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model.

Company Type
Twitter Account
@OFX
News Page URL
Click here

Oncimmune

Oncimmune’s intimate understanding of the human immune system enables the Company to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.

The key to improving cancer survival is early detection and optimal selection for therapy. Oncimmune is driven by a passion to improve cancer survival and to give people extra time. Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.​

Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful NHS Early detection of Cancer of the Lung (ECLS) trial of 12,209 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Headquartered at its laboratory facility in Nottingham, UK, Oncimmune has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

Company Type
Keywords
Twitter Account
@OncimmuneECDT
News Page URL
Click here

One Nucleus

One Nucleus is a Cambridge/London Life Science membership organisation. We support Europe’s largest Life Science cluster encompassing the London-Cambridge-East of England region via knowledge transfer, connectivity, inward investment and growth.

Company Type
Twitter Account
@OneNucleus
News Page URL
Click here